FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891826085> ?p ?o ?g. }

• W2891826085 endingPage "607" @default.
• W2891826085 startingPage "601" @default.
• W2891826085 abstract "We sought to develop a safe and effective outpatient salvage regimen by replacing ifosfamide within the (R)ICE (rituximab, ifosfomide, carboplatin, etoposide) regimen with bendamustine (T(R)EC) via a multicentre phase I/II study for patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) and classic Hodgkin lymphoma (HL). Therapy consisted of 60-120 mg/m2 per day bendamustine on days 1 and 2 in combination with carboplatin, etoposide and rituximab (only for CD20+ lymphoma) used in the (R)ICE regimen for up to 2 cycles. The objectives were to define a maximally tolerated dose (MTD) of bendamustine, determine safety and toxicity, assess efficacy, and evaluate impact on stem cell collection. Forty-eight patients were treated of which 71% had refractory disease. No dose-limiting toxicities were observed. The recommended phase II dose of bendamustine was 120 mg/m2 per day on days 1 and 2. Response rates were 85% (70% complete response, CR) in HL, and 65% (40% CR) in DLBCL. Stem cell collection was successful in 30 of 32 patients. The most common non-haematological toxicities ≥grade 3 were febrile neutropenia (8%) and dehydration (8%). The T(R)EC regimen safely yields high response rates, successfully mobilizes peripheral blood stem cells and compares favourably to RICE, offering an effective outpatient treatment option for patients with relapsed or refractory DLBCL and HL." @default.
• W2891826085 created "2018-09-27" @default.
• W2891826085 creator A5004025497 @default.
• W2891826085 creator A5004429744 @default.
• W2891826085 creator A5008481093 @default.
• W2891826085 creator A5023180146 @default.
• W2891826085 creator A5023949296 @default.
• W2891826085 creator A5049229364 @default.
• W2891826085 creator A5049498908 @default.
• W2891826085 creator A5059661907 @default.
• W2891826085 creator A5064520181 @default.
• W2891826085 creator A5076234599 @default.
• W2891826085 creator A5077272360 @default.
• W2891826085 creator A5081386100 @default.
• W2891826085 creator A5082326885 @default.
• W2891826085 creator A5084492085 @default.
• W2891826085 creator A5088459737 @default.
• W2891826085 date "2018-09-14" @default.
• W2891826085 modified "2023-10-14" @default.
• W2891826085 title "Bendamustine with rituximab, etoposide and carboplatin (T(R)EC) in relapsed or refractory aggressive lymphoma: a prospective multicentre phase 1/2 clinical trial" @default.
• W2891826085 cites W1975124426 @default.
• W2891826085 cites W1978849352 @default.
• W2891826085 cites W2000420043 @default.
• W2891826085 cites W2039175138 @default.
• W2891826085 cites W2044603680 @default.
• W2891826085 cites W2107433970 @default.
• W2891826085 cites W2120755425 @default.
• W2891826085 cites W2122654415 @default.
• W2891826085 cites W2125616358 @default.
• W2891826085 cites W2131998596 @default.
• W2891826085 cites W2133201432 @default.
• W2891826085 cites W2133345449 @default.
• W2891826085 cites W2150587745 @default.
• W2891826085 cites W2153280042 @default.
• W2891826085 cites W2164814247 @default.
• W2891826085 cites W2169209759 @default.
• W2891826085 cites W2336054546 @default.
• W2891826085 cites W2403089702 @default.
• W2891826085 cites W2463754429 @default.
• W2891826085 cites W2473498748 @default.
• W2891826085 cites W2570618306 @default.
• W2891826085 cites W2598700764 @default.
• W2891826085 cites W2803000479 @default.
• W2891826085 cites W67299084 @default.
• W2891826085 doi "https://doi.org/10.1111/bjh.15585" @default.
• W2891826085 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6314205" @default.
• W2891826085 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30596402" @default.
• W2891826085 hasPublicationYear "2018" @default.
• W2891826085 type Work @default.
• W2891826085 sameAs 2891826085 @default.
• W2891826085 citedByCount "7" @default.
• W2891826085 countsByYear W28918260852020 @default.
• W2891826085 countsByYear W28918260852021 @default.
• W2891826085 countsByYear W28918260852022 @default.
• W2891826085 crossrefType "journal-article" @default.
• W2891826085 hasAuthorship W2891826085A5004025497 @default.
• W2891826085 hasAuthorship W2891826085A5004429744 @default.
• W2891826085 hasAuthorship W2891826085A5008481093 @default.
• W2891826085 hasAuthorship W2891826085A5023180146 @default.
• W2891826085 hasAuthorship W2891826085A5023949296 @default.
• W2891826085 hasAuthorship W2891826085A5049229364 @default.
• W2891826085 hasAuthorship W2891826085A5049498908 @default.
• W2891826085 hasAuthorship W2891826085A5059661907 @default.
• W2891826085 hasAuthorship W2891826085A5064520181 @default.
• W2891826085 hasAuthorship W2891826085A5076234599 @default.
• W2891826085 hasAuthorship W2891826085A5077272360 @default.
• W2891826085 hasAuthorship W2891826085A5081386100 @default.
• W2891826085 hasAuthorship W2891826085A5082326885 @default.
• W2891826085 hasAuthorship W2891826085A5084492085 @default.
• W2891826085 hasAuthorship W2891826085A5088459737 @default.
• W2891826085 hasBestOaLocation W28918260851 @default.
• W2891826085 hasConcept C126322002 @default.
• W2891826085 hasConcept C141071460 @default.
• W2891826085 hasConcept C143998085 @default.
• W2891826085 hasConcept C2776694085 @default.
• W2891826085 hasConcept C2777063308 @default.
• W2891826085 hasConcept C2778119113 @default.
• W2891826085 hasConcept C2778239845 @default.
• W2891826085 hasConcept C2778850193 @default.
• W2891826085 hasConcept C2779338263 @default.
• W2891826085 hasConcept C2780653079 @default.
• W2891826085 hasConcept C2780775027 @default.
• W2891826085 hasConcept C2781413609 @default.
• W2891826085 hasConcept C2781442060 @default.
• W2891826085 hasConcept C2781451048 @default.
• W2891826085 hasConcept C31760486 @default.
• W2891826085 hasConcept C71924100 @default.
• W2891826085 hasConcept C90924648 @default.
• W2891826085 hasConceptScore W2891826085C126322002 @default.
• W2891826085 hasConceptScore W2891826085C141071460 @default.
• W2891826085 hasConceptScore W2891826085C143998085 @default.
• W2891826085 hasConceptScore W2891826085C2776694085 @default.
• W2891826085 hasConceptScore W2891826085C2777063308 @default.
• W2891826085 hasConceptScore W2891826085C2778119113 @default.
• W2891826085 hasConceptScore W2891826085C2778239845 @default.
• W2891826085 hasConceptScore W2891826085C2778850193 @default.
• W2891826085 hasConceptScore W2891826085C2779338263 @default.
• W2891826085 hasConceptScore W2891826085C2780653079 @default.

• next